Alnylam Pharmaceuticals, Inc. (ALNY), the RNA interference (RNAi) therapeutics pioneer, saw its analyst target landscape reset sharply after its October 29, 2026 third-quarter report. Reviewing 14 current targets that identify the analyst, firm, and date, the range runs from a low of $199 (Bernstein, Market Perform) to a high of $410 (Piper Sandler, Buy). The arithmetic mean of these targets is about $301, rounded to a central target of $300.
The dispersion is unusually wide, reflecting genuine disagreement. Bulls such as Barclays ($380), TD Cowen ($354), and Goldman Sachs ($320) emphasize the long-term ATTR amyloidosis opportunity. More cautious voices — Truist ($225, downgraded to Hold), Morgan Stanley ($240, Equal Weight), and Bernstein ($199, downgraded to Market Perform) — cite a less certain Amvuttra outlook and the enrollment expansion of the TRITON-CM Phase 3 trial of nucresiran. These downgrades and target cuts are materially relevant because they follow a stock that has already fallen sharply from its 52-week high near $480.
With shares trading near $165, the $300 central target implies roughly 82% upside, a very large required move. The stock sits far below its 52-week high of roughly $480 and only modestly above its 52-week low near $149.
Fundamentals are mixed. Third-quarter 2026 net product revenue rose 52% year over year to about $1.29 billion, led by $1.13 billion of Amvuttra sales (up 65%). Yet management acknowledged that underlying Amvuttra demand growth has not met expectations and guided full-year TTR revenue toward the low end of its $4.2–$4.5 billion range. Reported GAAP net income of $2.17 billion was inflated by an approximately $1.9 billion non-cash tax benefit, so investors should focus on the operating picture rather than the headline profit.
The TTR franchise remains the engine, with roughly 80% of prevalent ATTR-CM (transthyretin amyloid cardiomyopathy) patients still untreated. Amvuttra holds about 24% of total TTR-category prescriptions, and its new-to-brand share has stayed above 30%. A strong balance sheet — about $3.6 billion in cash and marketable securities — funds continued commercial investment and pipeline development, including the Huntington's disease program brezosiran and next-generation nucresiran. Reacceleration of Amvuttra demand growth, favorable resolution of the 340B reimbursement uncertainty, and positive clinical readouts would all support a higher valuation.
The principal obstacle is Amvuttra's demand trajectory. A more restrictive UnitedHealth Medicare Advantage policy and a proposed CMS 340B rule that could reduce Part B reimbursement create near-term uncertainty around pricing, volume, and ordering patterns. Competition in ATTR-CM, a longer runway before nucresiran's potential 2030 launch, and valuation compression in a risk-off biotech tape all present headwinds. The wide analyst range — from $199 to $410 — signals that even professionals disagree substantially on whether the current reset is overdone or justified.
Technically, the stock has transitioned from a long-term uptrend to a downtrend in 2026, losing roughly two-thirds of its value from the high. The 52-week low near $149 stands as key support, while prior consolidation zones and the psychological $200 level represent resistance on any recovery. A durable reclaim of the $200 area would be an early signal that the post-earnings decline may be stabilizing, but the stock remains well below its longer-term trend structure.
Most analyst price targets reflect a roughly 12-month research horizon, though individual timelines vary. Investors should watch Amvuttra prescription and demand trends, updates on the 340B rule, the two-year HELIOS-B open-label extension data and indirect treatment comparison presented at medical meetings, and the company's 2027 product revenue guidance, now expected in mid-February rather than at the January JPMorgan conference. Any further analyst revisions around these events will shape whether the $300 central target moves up or down.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like ALNY, which has experienced rapid target revisions and sharp price swings, these signals can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Traders seeking a systematic edge may find it useful to explore these signals alongside their own research.
The question of whether Alnylam can reach $300 is, in essence, a question about whether Amvuttra demand reaccelerates and whether the pipeline justifies the premium bulls still assign. The $300 central target, averaging 14 analyst views spanning $199 to $410, sits roughly 82% above the current price, making it a demanding threshold rather than a modest recovery. Strong franchise growth, an underpenetrated market, and a robust balance sheet provide the foundation, while softer demand, reimbursement uncertainty, and competition weigh against a rapid advance. With analyst opinion so divided, the stock's path will likely hinge on forthcoming demand data and the February 2027 guidance update, which investors should monitor closely before drawing conclusions about the $300 level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with INO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then INO could also see price increases.
| Ticker / NAME | Correlation To ALNY | 1D Price Change % | ||
|---|---|---|---|---|
| ALNY | 100% | -3.22% | ||
| INO - ALNY | 44% Loosely correlated | -2.10% | ||
| PHAT - ALNY | 40% Loosely correlated | -2.97% | ||
| UTHR - ALNY | 35% Loosely correlated | -0.56% | ||
| AXON - ALNY | 35% Loosely correlated | -2.85% | ||
| BCRX - ALNY | 33% Loosely correlated | -2.10% | ||
More | ||||